Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) dropped 3.3% during mid-day trading on Monday . The company traded as low as $13.78 and last traded at $13.94. Approximately 298,510 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 1,682,431 shares. The stock had previously closed at $14.41.
Wall Street Analysts Forecast Growth
DYN has been the topic of a number of recent research reports. Raymond James Financial initiated coverage on Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 target price on the stock. Robert W. Baird cut their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday. HC Wainwright cut their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Scotiabank initiated coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.93.
Get Our Latest Stock Analysis on Dyne Therapeutics
Dyne Therapeutics Price Performance
The business has a fifty day moving average of $11.54 and a 200-day moving average of $14.71. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.00 and a beta of 1.16.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the fourth quarter worth about $50,000. GAMMA Investing LLC increased its stake in Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after purchasing an additional 2,345 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after purchasing an additional 2,446 shares in the last quarter. Quarry LP purchased a new position in Dyne Therapeutics in the 1st quarter worth about $47,000. Finally, Summit Investment Advisors Inc. increased its stake in Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.